A beneficial levels of 25-hydroxyvitamin D for a decrease in thyrotropin receptor antibody (TRAB) in patients with Graves’ disease: a real-world study
Abstract Objective This study aimed to determine whether a relationship exist between pre-therapy 25-hydroxyvitamin D levels and the remission/negative conversion rates of thyrotropin receptor antibody (TRAB) during treatment in patients with newly diagnosed Graves’ disease (GD). Methods 171 patient...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | BMC Endocrine Disorders |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12902-024-01823-x |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832585622842245120 |
|---|---|
| author | Xide Chen Yongze Zhang Luxi Lin Yuxia Chen Ximei Shen Lingning Huang Fengying Zhao Sunjie Yan |
| author_facet | Xide Chen Yongze Zhang Luxi Lin Yuxia Chen Ximei Shen Lingning Huang Fengying Zhao Sunjie Yan |
| author_sort | Xide Chen |
| collection | DOAJ |
| description | Abstract Objective This study aimed to determine whether a relationship exist between pre-therapy 25-hydroxyvitamin D levels and the remission/negative conversion rates of thyrotropin receptor antibody (TRAB) during treatment in patients with newly diagnosed Graves’ disease (GD). Methods 171 patients were included from the Endocrinology Department of the First Affiliated Hospital of Fujian Medical University in March 2013 to April 2016. Ninety-five patients of them were diagnosed at our hospital but transferred to local hospitals for treatment. Seventy-six patients were followed and treated at our hospital with a median follow-up time of 11.03 (range 6–27) months. Patients were divided into 3 groups according to baseline 25-hydroxyvitamin D levels; <20 ng/mL (31,43.05%), 20–29 ng /mL (20,27.78%), and ≥ 30 ng/mL (20,29.17%). The TRAB remission rate and negative conversion rate was assessed among each group. Results There was a higher TSH and lower TRAB titer in the 20–29 ng/mL group at initial diagnosis. Cox regression analysis suggested that 20–29 ng/mL group had significantly higher remission rates [RR; 95% CI: 7.505 (1.401–40.201), 8.975 (2.759–29.196),6.853(2.206–21.285), respectively] and negative conversion rates [RR; 95% CI: 7.835 (1.468–41.804),7.189(1.393–37.092), 8.122(1.621–40.688)] at the 6-, 12-, and 24-month follow-up, respectively . The level of 25-hydroxyvitamin D at the time of initial diagnosis was not associated with the re-normal of free Triiodothyronine(FT3), free thyroxineIndex(FT4) or TSH levels during the follow-up. Conclusion Newly diagnosed GD patients with appropriate baseline 25-hydroxyvitamin D levels (20–29 ng/mL) are beneficial for the reduction of TRAB during antithyroid therapy. |
| format | Article |
| id | doaj-art-2adbd75819cb4115a7997c69d43d186e |
| institution | Kabale University |
| issn | 1472-6823 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Endocrine Disorders |
| spelling | doaj-art-2adbd75819cb4115a7997c69d43d186e2025-01-26T12:37:38ZengBMCBMC Endocrine Disorders1472-68232025-01-0125111010.1186/s12902-024-01823-xA beneficial levels of 25-hydroxyvitamin D for a decrease in thyrotropin receptor antibody (TRAB) in patients with Graves’ disease: a real-world studyXide Chen0Yongze Zhang1Luxi Lin2Yuxia Chen3Ximei Shen4Lingning Huang5Fengying Zhao6Sunjie Yan7Department of Endocrinology, The First Affiliated Hospital, Fujian Medical UniversityDepartment of Endocrinology, The First Affiliated Hospital, Fujian Medical UniversityDepartment of Endocrinology, The First Affiliated Hospital, Fujian Medical UniversityDepartment of Endocrinology, The First Affiliated Hospital, Fujian Medical UniversityDepartment of Endocrinology, The First Affiliated Hospital, Fujian Medical UniversityDepartment of Endocrinology, The First Affiliated Hospital, Fujian Medical UniversityDepartment of Endocrinology, The First Affiliated Hospital, Fujian Medical UniversityDepartment of Endocrinology, The First Affiliated Hospital, Fujian Medical UniversityAbstract Objective This study aimed to determine whether a relationship exist between pre-therapy 25-hydroxyvitamin D levels and the remission/negative conversion rates of thyrotropin receptor antibody (TRAB) during treatment in patients with newly diagnosed Graves’ disease (GD). Methods 171 patients were included from the Endocrinology Department of the First Affiliated Hospital of Fujian Medical University in March 2013 to April 2016. Ninety-five patients of them were diagnosed at our hospital but transferred to local hospitals for treatment. Seventy-six patients were followed and treated at our hospital with a median follow-up time of 11.03 (range 6–27) months. Patients were divided into 3 groups according to baseline 25-hydroxyvitamin D levels; <20 ng/mL (31,43.05%), 20–29 ng /mL (20,27.78%), and ≥ 30 ng/mL (20,29.17%). The TRAB remission rate and negative conversion rate was assessed among each group. Results There was a higher TSH and lower TRAB titer in the 20–29 ng/mL group at initial diagnosis. Cox regression analysis suggested that 20–29 ng/mL group had significantly higher remission rates [RR; 95% CI: 7.505 (1.401–40.201), 8.975 (2.759–29.196),6.853(2.206–21.285), respectively] and negative conversion rates [RR; 95% CI: 7.835 (1.468–41.804),7.189(1.393–37.092), 8.122(1.621–40.688)] at the 6-, 12-, and 24-month follow-up, respectively . The level of 25-hydroxyvitamin D at the time of initial diagnosis was not associated with the re-normal of free Triiodothyronine(FT3), free thyroxineIndex(FT4) or TSH levels during the follow-up. Conclusion Newly diagnosed GD patients with appropriate baseline 25-hydroxyvitamin D levels (20–29 ng/mL) are beneficial for the reduction of TRAB during antithyroid therapy.https://doi.org/10.1186/s12902-024-01823-xGraves’disease, 25-hydroxyvitamin DTRAB remission rateNegative conversion rateThyroid function |
| spellingShingle | Xide Chen Yongze Zhang Luxi Lin Yuxia Chen Ximei Shen Lingning Huang Fengying Zhao Sunjie Yan A beneficial levels of 25-hydroxyvitamin D for a decrease in thyrotropin receptor antibody (TRAB) in patients with Graves’ disease: a real-world study BMC Endocrine Disorders Graves’disease, 25-hydroxyvitamin D TRAB remission rate Negative conversion rate Thyroid function |
| title | A beneficial levels of 25-hydroxyvitamin D for a decrease in thyrotropin receptor antibody (TRAB) in patients with Graves’ disease: a real-world study |
| title_full | A beneficial levels of 25-hydroxyvitamin D for a decrease in thyrotropin receptor antibody (TRAB) in patients with Graves’ disease: a real-world study |
| title_fullStr | A beneficial levels of 25-hydroxyvitamin D for a decrease in thyrotropin receptor antibody (TRAB) in patients with Graves’ disease: a real-world study |
| title_full_unstemmed | A beneficial levels of 25-hydroxyvitamin D for a decrease in thyrotropin receptor antibody (TRAB) in patients with Graves’ disease: a real-world study |
| title_short | A beneficial levels of 25-hydroxyvitamin D for a decrease in thyrotropin receptor antibody (TRAB) in patients with Graves’ disease: a real-world study |
| title_sort | beneficial levels of 25 hydroxyvitamin d for a decrease in thyrotropin receptor antibody trab in patients with graves disease a real world study |
| topic | Graves’disease, 25-hydroxyvitamin D TRAB remission rate Negative conversion rate Thyroid function |
| url | https://doi.org/10.1186/s12902-024-01823-x |
| work_keys_str_mv | AT xidechen abeneficiallevelsof25hydroxyvitamindforadecreaseinthyrotropinreceptorantibodytrabinpatientswithgravesdiseasearealworldstudy AT yongzezhang abeneficiallevelsof25hydroxyvitamindforadecreaseinthyrotropinreceptorantibodytrabinpatientswithgravesdiseasearealworldstudy AT luxilin abeneficiallevelsof25hydroxyvitamindforadecreaseinthyrotropinreceptorantibodytrabinpatientswithgravesdiseasearealworldstudy AT yuxiachen abeneficiallevelsof25hydroxyvitamindforadecreaseinthyrotropinreceptorantibodytrabinpatientswithgravesdiseasearealworldstudy AT ximeishen abeneficiallevelsof25hydroxyvitamindforadecreaseinthyrotropinreceptorantibodytrabinpatientswithgravesdiseasearealworldstudy AT lingninghuang abeneficiallevelsof25hydroxyvitamindforadecreaseinthyrotropinreceptorantibodytrabinpatientswithgravesdiseasearealworldstudy AT fengyingzhao abeneficiallevelsof25hydroxyvitamindforadecreaseinthyrotropinreceptorantibodytrabinpatientswithgravesdiseasearealworldstudy AT sunjieyan abeneficiallevelsof25hydroxyvitamindforadecreaseinthyrotropinreceptorantibodytrabinpatientswithgravesdiseasearealworldstudy AT xidechen beneficiallevelsof25hydroxyvitamindforadecreaseinthyrotropinreceptorantibodytrabinpatientswithgravesdiseasearealworldstudy AT yongzezhang beneficiallevelsof25hydroxyvitamindforadecreaseinthyrotropinreceptorantibodytrabinpatientswithgravesdiseasearealworldstudy AT luxilin beneficiallevelsof25hydroxyvitamindforadecreaseinthyrotropinreceptorantibodytrabinpatientswithgravesdiseasearealworldstudy AT yuxiachen beneficiallevelsof25hydroxyvitamindforadecreaseinthyrotropinreceptorantibodytrabinpatientswithgravesdiseasearealworldstudy AT ximeishen beneficiallevelsof25hydroxyvitamindforadecreaseinthyrotropinreceptorantibodytrabinpatientswithgravesdiseasearealworldstudy AT lingninghuang beneficiallevelsof25hydroxyvitamindforadecreaseinthyrotropinreceptorantibodytrabinpatientswithgravesdiseasearealworldstudy AT fengyingzhao beneficiallevelsof25hydroxyvitamindforadecreaseinthyrotropinreceptorantibodytrabinpatientswithgravesdiseasearealworldstudy AT sunjieyan beneficiallevelsof25hydroxyvitamindforadecreaseinthyrotropinreceptorantibodytrabinpatientswithgravesdiseasearealworldstudy |